• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Effects of Intravenous Solanezumab 400 mg q 4 Weeks vs. Placebo on Biomarkers in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies (P01.011)
CONCLUSIONS: Solanezumab target engagement is associated with alteration of amyloid biology. There was a lack of apparent effect on markers of neurodegeneration. The overall findings lend support for the amyloid cascade hypothesis and suggest that various aspects of the cascade are viable targets for treatment of Alzheimer's disease.Supported by: Eli Lilly and Co.Disclosure: Dr. Hake has received personal compensation for activities with Eli Lilly and Company as an employee. Dr. Hake holds stock in Eli Lilly and Company. Dr. Siemers has received personal compensation for activities with Eli Lilly and Company as an employee...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Hake, A., Siemers, E., Carlson, C., Estergard, W., Sundell, K., Henley, D., Eads, J., Sexton, C., Liu-Seifert, H., Sethuraman, G., Chen, Y.-F., Mintun, M., Pontecorvo, M., Joshi, A., Dean, R., Willis, B., Demattos, R., Mohs, R. Tags: P01 Aging and Dementia: Therapeutics and Clinical Trials Source Type: research